290 related articles for article (PubMed ID: 38262842)
1. Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease.
Armandi A; Bugianesi E
Eur J Intern Med; 2024 Apr; 122():20-27. PubMed ID: 38262842
[TBL] [Abstract][Full Text] [Related]
2. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
; ;
Obes Facts; 2024 Jun; ():1-70. PubMed ID: 38852583
[TBL] [Abstract][Full Text] [Related]
3. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
; ; ;
J Hepatol; 2024 Jun; ():. PubMed ID: 38851997
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic management of metabolic dysfunction associated steatotic liver disease.
Zeng J; Fan JG; Francque SM
United European Gastroenterol J; 2024 Mar; 12(2):177-186. PubMed ID: 38193865
[TBL] [Abstract][Full Text] [Related]
5. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
[TBL] [Abstract][Full Text] [Related]
6. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
[TBL] [Abstract][Full Text] [Related]
7. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Backer S; Khanna D
Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
[TBL] [Abstract][Full Text] [Related]
8. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
Burmeister Y; Weyer K; Dörre A; Seilheimer B
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
[TBL] [Abstract][Full Text] [Related]
9. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.
Abushamat LA; Shah PA; Eckel RH; Harrison SA; Barb D
Clin Gastroenterol Hepatol; 2024 Feb; ():. PubMed ID: 38367743
[TBL] [Abstract][Full Text] [Related]
10. A review regarding the article 'Electrocardiographic abnormalities in patients with metabolic dysfunction-associated Steatotic liver disease: A systematic review and meta-analysis.'.
Li C; Wang T; Song J
Curr Probl Cardiol; 2024 Jul; 49(7):102626. PubMed ID: 38718937
[TBL] [Abstract][Full Text] [Related]
11. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
[TBL] [Abstract][Full Text] [Related]
12. Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.
Ortiz-López N; Madrid AM; Aleman L; Zazueta A; Smok G; Valenzuela-Pérez L; Poniachik J; Beltrán CJ
Front Med (Lausanne); 2024; 11():1376148. PubMed ID: 38854668
[TBL] [Abstract][Full Text] [Related]
13. Can liquid biopsies for MASH help increase the penetration of metabolic surgery? A narrative review.
Castagneto-Gissey L; Bornstein SR; Mingrone G
Metabolism; 2024 Feb; 151():155721. PubMed ID: 37923007
[TBL] [Abstract][Full Text] [Related]
14. The pathophysiology of MASLD: an immunometabolic perspective.
Schwärzler J; Grabherr F; Grander C; Adolph TE; Tilg H
Expert Rev Clin Immunol; 2024 Apr; 20(4):375-386. PubMed ID: 38149354
[TBL] [Abstract][Full Text] [Related]
15. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
Takahashi Y; Dungubat E; Kusano H; Fukusato T
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
[TBL] [Abstract][Full Text] [Related]
16. Can Nutraceuticals Support the Treatment of MASLD/MASH, and thus Affect the Process of Liver Fibrosis?
Sokal-Dembowska A; Jarmakiewicz-Czaja S; Ferenc K; Filip R
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791276
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Muddle. MASLD and MASH on the Horizon.
Meagher T
J Insur Med; 2023 Jul; 50(2):147-149. PubMed ID: 38358924
[TBL] [Abstract][Full Text] [Related]
18. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
Noureddin N; Copur-Dahi N; Loomba R
Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1(Suppl 1):S41-S51. PubMed ID: 38813822
[TBL] [Abstract][Full Text] [Related]
19. The potential role of omentin-1 in obesity-related metabolic dysfunction-associated steatotic liver disease: evidence from translational studies.
Salvoza N; Giraudi P; Gazzin S; Bonazza D; Palmisano S; de Manzini N; Zanconati F; Raseni A; Sirianni F; Tiribelli C; Rosso N
J Transl Med; 2023 Dec; 21(1):906. PubMed ID: 38082368
[TBL] [Abstract][Full Text] [Related]
20. NIS2+
Ratziu V; Harrison SA; Hajji Y; Magnanensi J; Petit S; Majd Z; Delecroix E; Rosenquist C; Hum D; Staels B; Anstee QM; Sanyal AJ
J Hepatol; 2024 Feb; 80(2):209-219. PubMed ID: 38061448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]